PDCD1 and neoplasm: The up-regulation of Tbet transcription, which in turn inhibits PD-1 and LAG-3 transcription, has been suggested as the molecular mechanism underlying the anti-tumor activity of GSK-3 inactivation or deletion in T cells [19].